Yesterday
Why clinical labs are hot property for asset managers
Wentworth Capital is eyeing a further $600 million in life science property investments with BlackRock.
This Month
Telix subpoenaed by US regulator over cancer therapy
The Melbourne-based biotech says it has notified ASIC about the investigation by US regulators.
How an introvert’s brand raked in $8m in sales
Hayden Brass knew his humble family business could be more. Now the founder of health and wellness company Zea is a 2025 BOSS Young Executive.
Jefferies, Mayne Pharma in spotlight after suitor’s court win
US medicines giant Cosette has successfully sought confidential modelling that it says could prove it was given incomplete financial information.
Mesoblast shares soar 35pc on strong cell therapy sales data
The biotech says sales of its first commercial therapy, Ryoncil, were $20 million in the quarter ending June 30.
Armitage readies healthtech for sale, tapping Houlihan Lokey
Mark De Ambrosis’ Armitage first bought into MYP in December 2020, acquiring a stake just north of 50 per cent.
Waiting to get rich from biotech? Don’t hold your breath
Regulatory upheaval in the US and a venture capital drought are dampening investor appetites, but there are still diamonds in the rough.
The 10 wealthiest executives in the ASX 300 revealed
Healthcare and tech company bosses, including the co-founders of the ASX’s newest $30 billion company Pro Medicus, dominate the Rich Bosses list.
Healthscope’s not-for-profit plan to bid for itself
Healthscope’s lenders are weighing up a proposal to restructure the hospital operator into a not-for-profit company which will save $100 million on payroll tax.
AI is giving private equity a new headache
The local boss of US private equity group Riverside Company says a kid can use AI to replicate a company’s software in hours. That’s a big new risk to price in.
New tech deal alert: General Atlantic hires advisers to sell $1b Mable
Mable, a marketplace platform that works with NDIS participants and at-home carers, was founded in 2014 by Peter Scutt and Tony Charara.
Stop the mental health blowout, says Labor MP
Paediatrician and MP Mike Freelander says the way society diagnoses mental health is part of the problem behind a huge rise in compensation claims.
CSL prepares to slash R&D as it grapples with looming Trump tariffs
The market is focused on a mooted 200 per cent levy on the pharmaceutical giant’s goods. There are far more significant changes afoot at the company.
Health insurer promotion frenzy draws federal government scrutiny
Dozens of funds are offering free cover for up to three months, saving members thousands of dollars if they sign up. Worries about how they work are growing.
Target hostile countries, not us, drug giant CSL tells Trump
The country’s biggest pharmaceuticals group pointed to “specific non-allied countries” and urged the White House to reconsider a 200 per cent tariff.
No gaps: Is this the future of private hospitals?
A combination of doctors’ frustration, an available site and a developer looking to expand led to the building of a $100 million hospital.
Healthscope’s problems are huge, Tino La Spina says he can fix it
While the company’s receivers are being pressured to break up the hospital group, there is also an alternative vision to keep it whole.
The pharmacists who made millions from Chemist Warehouse’s IPO
The retailer’s co-founders are well-known billionaires, but its backdoor listing with Sigma made hundreds of its store managers multimillionaires overnight.
Greg Hunt says states should pay private hospitals for public beds
The former health minister is now a senior adviser at Alvarez & Marsal. He says public funding could help the struggling sector and cut down waiting lists.
Microsoft claims AI diagnostic tool can outperform doctors
The new system is underpinned by a so-called “orchestrator” that creates virtual panels of five AI agents acting as “doctors”, each with a distinct role.